Integrating new oral selective oestrogen receptor degraders in the breast cancer treatment. | Curr Opin Oncol;34(6): 635-642, 2022 11 01. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Integrating new oral selective oestrogen receptor degraders in the breast cancer treatment.

Garcia-Fructuoso, Isabel; Gomez-Bravo, Raquel; Schettini, Francesco.

Affiliation

Garcia-Fructuoso I; Department of Medical Oncology, Hospital Clinic of Barcelona.
Gomez-Bravo R; Department of Medical Oncology, Hospital Clinic of Barcelona.
Schettini F; Department of Medical Oncology, Hospital Clinic of Barcelona.

Curr Opin Oncol ; 34(6): 635-642, 2022 11 01.

Article in En | MEDLINE | ID: mdl-36000362

Subject(s)

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Limits: Female / Humans Language: En Journal: Curr Opin Oncol Journal subject: NEOPLASIAS Year: 2022 Document type: Article Country of publication:

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Limits: Female / Humans Language: En Journal: Curr Opin Oncol Journal subject: NEOPLASIAS Year: 2022 Document type: Article Country of publication: